AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00768781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
Study NCT00768781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Therapy for Insomnia
Description: MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
Study NCT00768781 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-List + Behavioral Therapy for Insomnia
Description: This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
Study NCT02261688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low salt diet
Description: Low salt diet, 10mmoL of sodium per day, for 6 days
Study NCT02261688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low salt diet + IV normal saline
Description: Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
Study NCT02261688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Liberal salt diet
Description: Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
Study NCT00620217 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intramyocardial injection of VEGF-A165/bFGF:placebo plasmid
Description: The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
Study NCT00620217 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: intramyocardial injection of VEGF-A165/bFGF:placebo plasmid
Description: The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
Study NCT03558204 — intervention group
Intervention type: PROCEDURE
Intervention: Denervation of the thumb CMC joint
Description: Removal/disconnection of the nerve branches to the joint from their attachments to the joint
Study NCT03558204 — intervention group
Intervention type: PROCEDURE
Intervention: trapeziectomy with ligament reconstruction (LRTI)
Description: excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
Study NCT01535989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: starting dose 0.8 mg/m2, d1 administration, q4wks
Study NCT01535989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: starting dose of 15mg, weekly administration, q4ws
Study NCT02716649 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03168204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored care and support
Description: Offering tailored care and support whereby the competences, strengths and resources of the older person are taken into account.The intervention will be an enhancement of usual care and will depend on the availability of the municipality, and could be formal (i.e., home care) or informal (e.g. activities of an older adult's association).
Study NCT01859312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (Solucortef)
Description: Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
Study NCT01859312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump (Medtronic)
Description: Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA)
Study NCT02023554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline with azithromycin
Description: Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7.
Study NCT02023554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline alone
Description: Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
Study NCT02087306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: BCV administered twice weekly, dose depending on weight.
Study NCT02960542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELP Prevent Cancer Intervention
Description: This Behavioral: Lifestyle Weigh Loss Intervention involves a dietary weight-loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight-loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight-loss of .3 kg/week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 minutes/week.
Study NCT01762241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based training using the Xbox Kinect system
Description: Home based training 3 times a week for 12 weeks using the Xbox Kinect system
Study NCT04154137 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
Study NCT01187576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-professional team intervention with PAR, lifestyle brochure
Description: Multi-professional team intervention with PAR, lifestyle brochure
Study NCT01187576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary recommendations on health behaviours, lifestyle brochure
Description: Ordinary recommendations on health behaviours, lifestyle brochure
Study NCT03684096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: non-estrogenic pollen extract PCC-100
Description: non-estrogenic pollen extract PCC-100
Study NCT03684096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo -non-estrogenic pollen extract PCC-100
Study NCT01558921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M1 scheme
Description: short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
Study NCT01558921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard long course chemoradiotherapy
Description: long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
Study NCT03601351 — intervention group
Intervention type: OTHER
Intervention: ELISA for MOR-1 expression
Description: To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.
Study NCT01821586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ORS-1
Study NCT01821586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ORS-2 (ReSoMal)
Study NCT01821586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ORS-3 (Benefibre)
Study NCT02945267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus S1
Description: Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
Study NCT02945267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus S1
Description: Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
Study NCT00344019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo pre-PCI for ACS
Study NCT00344019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: atorvastatin 80 mg pre-angio/PCI
Study NCT00344019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
Study NCT00344019 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Screening
Description: Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
Study NCT00843193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INTRAVENOUS GSK679586
Description: GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
Study NCT00843193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INTRAVENOUS PLACEBO
Description: Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
Study NCT00843193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUTICASONE PROPIONATE
Description: Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
Study NCT00843193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FLUTICASONE PROPIONATE
Description: Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
Study NCT01648140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 40 mg
Description: 20 mg tablet, round, 10-mm diameter, white to off-white, no markings
Study NCT01648140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 60 mg
Description: 30 mg tablet, round, 10-mm diameter, white to off-white, no markings
Study NCT01648140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a
Description: 180 microgram per 0.5 mL prefilled syringe for single use
Study NCT01648140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alpha-2a
Description: 180 microgram per 0.5 mL prefilled syringe for single use
Study NCT01648140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side
Study NCT02803931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiogoniometry
Description: Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
Study NCT02803931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 12-lead ECG
Study NCT01329224 — intervention group
Intervention type: OTHER
Intervention: Measurement of platelet anti-aggregation
Description: Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
Study NCT02730507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional straight rod
Description: Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
Study NCT02361762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized executive control training
Description: Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.~Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.~A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks.
Study NCT03665376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink load
Description: Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
Study NCT01648140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side
Study NCT01648140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: 375 mg film-coated tablet
Study NCT03665376 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Description: The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
Study NCT04346069 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PCIT (parent child interaction therapy)
Description: Parent child interaction therapy is a treatment strategy that nurture parent child relationship and teach effective parenting strategies to decrease child non compliance behavior (BodifordMcNeil; Hembree-Kigin, 2010).Parent-Child Interaction Therapy (PCIT; Eyberg; Robinson, 1982 ; Zisser; Eyberg, 2008 ) is a manualized parent training intervention that has received substantial empirical support in the treatment of disruptive behavior across multiple reviews (e.g., Brestan; Eyberg, 1998 ; Gallagher, 2003 ; Thomas \&amp; Zimmer-Gembeck, 2007 ). PCIT established strong relation among parenting, social learning, and attachment theories and proceeds.
Study NCT02296099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
Study NCT02296099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
Study NCT04382859 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transversus abdominis plane (TAP) block with liposomal bupivacaine
Description: Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).
Study NCT04382859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block with liposomal bupivacaine
Description: Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).
Study NCT02077075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based weight loss program
Description: A 4-week web-based wellness program.
Study NCT02077075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based weight loss program
Description: A 4-week web-based wellness program.
Study NCT02077075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-line health coaching
Description: A 4-week web-based wellness program with weekly personalized on-line health coaching.
Study NCT04196361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Point of care ultrasound as part of routine physical examination
Study NCT02822339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-030)
Study NCT03362671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Supported Mandibular Advancement Oral Appliance
Description: This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
Study NCT04564391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein supplement
Description: protein supplement, daily 60 g of protein, 3 weeks of intervention; blinded to patients
Study NCT03362671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic Mini Implant
Description: Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
Study NCT01055951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solo MicroPump
Description: 30 days treatment days with an optional extension period of up to 6 month of treatment.
Study NCT04667156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
Study NCT01201096 — intervention group
Intervention type: RADIATION
Intervention: 177Lutetium
Description: two cycles of 177Lutetium radioreceptor therapy within two month
Study NCT01201096 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: about 9 month after finishing the receptor therapy liver transplantation takes place
Study NCT00660036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.